新兴的腺苷受体激动剂：最新进展。
Emerging adenosine receptor agonists: an update.
出版信息
Expert Opin Emerg Drugs. 2011 Dec;16(4):597-602. doi: 10.1517/14728214.2011.644786. Epub 2011 Dec 7.
Abstract
Adenosine receptors (ARs), the major targets of caffeine and theophylline, comprise four receptor subtypes designated as A(1), A(2A), A(2B) and A(3). Over a dozen AR agonists are currently in clinical trials for various conditions, including cardiac arrhythmias, neuropathic pain, myocardial perfusion imaging, cardiac ischemia, inflammatory diseases and cancer. Adenosine (nonselective), regadenoson (A(2A)) and dipyridamole (act indirectly via ARs) have received regulatory approval for clinical use. The present editorial will give a brief update on the current status of AR agonists in clinical trials.
摘要
腺苷受体（ARs）是咖啡因和茶碱的主要靶点，包括四个受体亚型，分别命名为 A(1)、A(2A)、A(2B)和 A(3)。目前，有十几种 AR 激动剂正在进行各种疾病的临床试验，包括心律失常、神经性疼痛、心肌灌注成像、心肌缺血、炎症性疾病和癌症。腺苷（非选择性）、雷腺苷（A(2A)) 和双嘧达莫（通过 AR 间接作用）已获得监管部门批准用于临床。本社论将简要介绍 AR 激动剂在临床试验中的最新进展。
相似文献
1
Emerging adenosine receptor agonists: an update.
Expert Opin Emerg Drugs. 2011 Dec;16(4):597-602. doi: 10.1517/14728214.2011.644786. Epub 2011 Dec 7.
2
Emerging adenosine receptor agonists.
Expert Opin Emerg Drugs. 2007 Sep;12(3):479-92. doi: 10.1517/14728214.12.3.479.
3
Introduction to adenosine receptors as therapeutic targets.
Handb Exp Pharmacol. 2009(193):1-24. doi: 10.1007/978-3-540-89615-9_1.
4
G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.
Purinergic Signal. 2012 Sep;8(3):419-36. doi: 10.1007/s11302-012-9294-7. Epub 2012 Feb 29.
5
Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET.
Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1908-16. doi: 10.1007/s00259-011-1853-6. Epub 2011 Jun 9.
6
Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs.
Curr Top Med Chem. 2006;6(13):1375-99. doi: 10.2174/15680266106061375.
7
Adenosine receptor ligands-recent developments part I. Agonists.
Curr Med Chem. 2000 Dec;7(12):1269-88. doi: 10.2174/0929867003374101.
8
Recent developments in adenosine receptor ligands and their potential as novel drugs.
Biochim Biophys Acta. 2011 May;1808(5):1290-308. doi: 10.1016/j.bbamem.2010.12.017. Epub 2010 Dec 23.
9
A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats.
PLoS One. 2013;8(1):e54195. doi: 10.1371/journal.pone.0054195. Epub 2013 Jan 11.
10
Pain-relieving prospects for adenosine receptors and ectonucleotidases.
Trends Mol Med. 2011 Apr;17(4):188-96. doi: 10.1016/j.molmed.2010.12.006. Epub 2011 Jan 13.
引用本文的文献
1
Therapeutic potential of adenosine receptor modulators in cancer treatment.
RSC Adv. 2025 Jun 17;15(26):20418-20445. doi: 10.1039/d5ra02235e. eCollection 2025 Jun 16.
2
Design, synthesis and evaluation of amino-3,5-dicyanopyridines and thieno[2,3-b]pyridines as ligands of adenosine A receptors for the potential treatment of epilepsy.
Med Chem Res. 2022;31(8):1277-1297. doi: 10.1007/s00044-022-02908-9. Epub 2022 May 24.
3
Toward a Molecular Basis of Cellular Nucleoside Transport in Humans.
Chem Rev. 2021 May 12;121(9):5336-5358. doi: 10.1021/acs.chemrev.0c00644. Epub 2020 Nov 24.
4
Structural analysis, virtual screening and molecular simulation to identify potential inhibitors targeting 2'-O-ribose methyltransferase of SARS-CoV-2 coronavirus.
J Biomol Struct Dyn. 2022 Feb;40(3):1331-1346. doi: 10.1080/07391102.2020.1828172. Epub 2020 Oct 4.
5
Focusing on Adenosine Receptors as a Potential Targeted Therapy in Human Diseases.
Cells. 2020 Mar 24;9(3):785. doi: 10.3390/cells9030785.
6
Effect and Mechanism of Phosphodiesterase Inhibitors on Trabecular Outflow.
Korean J Ophthalmol. 2019 Oct;33(5):414-421. doi: 10.3341/kjo.2019.0057.
7
Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics.
Mol Pharmacol. 2017 Jan;91(1):25-38. doi: 10.1124/mol.116.105551. Epub 2016 Nov 1.
8
Analysis of Extracellular Nucleotide Metabolism in Adult Zebrafish After Embryological Exposure to Valproic Acid.
Mol Neurobiol. 2017 Jul;54(5):3542-3553. doi: 10.1007/s12035-016-9917-z. Epub 2016 May 17.
9
Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics.
Br J Pharmacol. 2016 Apr;173(8):1253-67. doi: 10.1111/bph.13446. Epub 2016 Mar 6.
10
Anti-inflammatory effects of adenosine N1-oxide.
J Inflamm (Lond). 2015 Jan 20;12(1):2. doi: 10.1186/s12950-014-0045-0. eCollection 2015.
本文引用的文献
1
Pharmacological and therapeutic effects of A3 adenosine receptor agonists.
Drug Discov Today. 2012 Apr;17(7-8):359-66. doi: 10.1016/j.drudis.2011.10.007. Epub 2011 Oct 19.
2
Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor.
J Pharmacol Exp Ther. 2012 Jan;340(1):210-7. doi: 10.1124/jpet.111.187559. Epub 2011 Oct 19.
3
Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers.
Biochem Pharmacol. 2011 Sep 15;82(6):658-68. doi: 10.1016/j.bcp.2011.06.017. Epub 2011 Jun 21.
4
Interplay of hypoxia and A2B adenosine receptors in tissue protection.
Adv Pharmacol. 2011;61:145-86. doi: 10.1016/B978-0-12-385526-8.00006-0.
5
Role of adenosine A(2B) receptors in inflammation.
Adv Pharmacol. 2011;61:115-44. doi: 10.1016/B978-0-12-385526-8.00005-9.
6
Structure of an agonist-bound human A2A adenosine receptor.
Science. 2011 Apr 15;332(6027):322-7. doi: 10.1126/science.1202793. Epub 2011 Mar 10.
7
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.
Pharmacol Rev. 2011 Mar;63(1):1-34. doi: 10.1124/pr.110.003285. Epub 2011 Feb 8.
8
Allosteric enhancers of A1 adenosine receptors: state of the art and new horizons for drug development.
Curr Med Chem. 2010;17(30):3488-502. doi: 10.2174/092986710792927831.
9
Recent developments in adenosine A2A receptor ligands.
Handb Exp Pharmacol. 2009(193):59-98. doi: 10.1007/978-3-540-89615-9_3.
10
A1 adenosine receptor agonists and their potential therapeutic applications.
Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10. doi: 10.1517/13543780802497284.
Zotero 插件